NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Romel Somwar et al. find that cancer-causing NTRK gene fusions resistant to one form of inhibitor therapy can be resistant to other inhibitor types. Using molecular simulations, they show that some NTRK1 mutations resistant to the type I inhibitor larotrectinib are hypersensitive to the type II inhi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Romel Somwar, Nicolle E. Hofmann, Bryan Smith, Igor Odintsov, Morana Vojnic, Irina Linkov, Ashley Tam, Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, Daniel Flynn, Marc Ladanyi, Alexander Drilon, Ujwal Shinde, Monika A. Davare
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Biology (General)
QH301-705.5
Acceso en línea:https://doaj.org/article/dc4dd666029c45298c0ddd64355c90c2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/dc4dd666029c45298c0ddd64355c90c2

Ejemplares similares